Durect Company Overview
About Durect
Durect (NASDAQ:DRRX) specializes in developing innovative drugs and therapies aimed at addressing acute and chronic health issues, focusing on areas such as pain management and other serious conditions. Traded on the NASDAQ stock exchange under the symbol DRRX, the company leverages its proprietary drug delivery technologies to improve the efficacy and safety profiles of existing and new pharmaceutical compounds. Durect's projects include advanced development programs for conditions that currently have limited treatment options, demonstrating its commitment to improving patient care and outcomes. The company's objectives center around advancing its research and development pipeline, securing partnerships to enhance market reach, and achieving regulatory approvals to bring transformative treatments to the healthcare market.
Snapshot
Operations
Produtos e/ou serviços de Durect
- DUR-928: An endogenous, small molecule in Phase 2 development for the treatment of alcoholic hepatitis, NASH, and other liver diseases.
- POSIMIR: A post-operative pain relief depot that delivers bupivacaine for up to 3 days after surgery.
- ALZET Osmotic Pumps: Implantable pumps for continuous, controlled in vivo drug delivery for research use.
- LACTEL Absorbable Polymers: Biodegradable polymers for controlled drug delivery, used in medical devices and pharmaceuticals.
- SABER Technology: A patented drug delivery platform designed to release drugs at a controlled rate for a period of days to months.
- ORADUR Technology: A technology that allows for the formulation of oral sustained release opioid products designed to discourage common methods of tampering.
equipe executiva do Durect
- Dr. James E. Brown D.V.M.Co-Founder, CEO, President & Director
- Mr. Timothy M. Papp M.B.A.CFO & Secretary
- Dr. Norman L. Sussman M.D.Chief Medical Officer
- Ms. Judy R. JoiceSenior Vice President of Operations & Corporate Quality Assurance
- Mr. Steve Helmer J.D.VP & Chief Patent Counsel
- Dr. WeiQi Lin M.D., Ph.D.Executive VP of Research & Development and Principal Scientist
- Ms. Jian Li M.B.A.SVP of Finance & Corporate Controller
- Dr. Su Il Yum Ph.D.Executive Officer